Oxygen Therapy for Retinal Ischemia

Retinal Ischemia Clinical Trial

Official title:
Normobaric Nocturnal Hyperoxia Therapy for Treating Ischemic-Related Retinal Conditions

Status Withdrawn

Clinical Trial Summary

The investigators will be using nocturnal normobaric hyperoxia therapy in patients with diagnoses of conditions related to retinal ischemia.

Clinical Trial Description

Patients who receive a diagnosis of a condition relate to retinal ischemia and who pass the eligibility criteria will receive an oxygen concentrator to use at home. They will report back in follow up monthly for three to six months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03730779
Study type	Interventional
Source	Beth Israel Deaconess Medical Center
Contact
Status	Withdrawn
Phase	Phase 4
Start date	November 30, 2018
Completion date	January 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03906383` - Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning in Patients With Type 1 Diabetes	N/A
Active, not recruiting	`NCT03422965` - Perifoveal Vascular Network Assessed by OCT-Angiography in Type I Diabetes Mellitus	N/A
Recruiting	`NCT03061526` - Spectral-domain Optical Coherence Tomography Findings in Retinal Vessel Occlusion
Completed	`NCT00841373` - Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease	Phase 1/Phase 2
Recruiting	`NCT04038125` - Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME	Phase 4